These data highlight a direct therapeutic role for hepatocyte NAMPT activation downstream of generalized fasting or hepatocyte GLUT inhibition, which can be utilized against obesity, aging, neurodegenerative, and other fasting-labile diseases. Here, SLC2A1 is linked to obesity due to melanocortin 4 receptor deficiency.